Sohanya Roshan Cheng - 15 Oct 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Commercial Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng
Issuer symbol
KPTI
Transactions as of
15 Oct 2025
Net transactions value
$0
Form type
4
Filing time
16 Oct 2025, 16:28:24 UTC
Previous filing
16 Sep 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cheng Sohanya Roshan EVP & Chief Commercial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng 16 Oct 2025 0001865796

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +43,650 +122% $0.000000 79,506 15 Oct 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.